InDevR launches a new product that could shave weeks off the timeline to deliver flu vaccines in the event of a pandemic BOULDER (2/20/18) -- InDevR, a Boulder-based analytical technology and life ...

BOULDER, CO--(Marketwired - May 21, 2015) - InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, announced the launch of the VaxArray™ ...

Panel of antibodies developed at Mount Sinai will enable first multiplexed potency assay for tracking neuraminidase in flu vaccines InDevR, a Boulder-based progressive analytical technology and life ...

Startled by the unexpected failure of a mid-stage trial of its vaccine adjuvant patch, Intercell AG is changing up the vaccine it used in the study along with the hemagglutinin inhibition assay used ...

A faulty hemagglutinin inhibition assay may be the reason underlying the failure of a Phase II clinical trial of Intercell AG's investigational Vaccine Enhancement Patch (VEP) for H5N1 influenza.

FDA develops an assay that could speed the release of pandemic influenza vaccines. A laboratory assay developed by scientists at FDA could speed the release of pandemic influenza vaccines to the ...

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics recently introduced Hemagglutination Inhibition Assay services to determine relative ...

Influenza Therapeutics with New Targets and Mechanisms of Action Are Urgently Needed Discovery of therapeutic agents typically follows predetermined paths guided by the specific molecular type of ...

The valiant effort to develop mRNA-based vaccines against pandemic coronavirus was not only successful but safe and efficacious vaccines were achieved in record time. While the analytical tools used ...

InDevR, a Boulder-based analytical technology and life science company, announced that it has expanded its VaxArray product portfolio with a new reagent kit to address the "need for speed" in ...